Companies: 48,874 Total Market Cap: 132104787226985.81

WuXi Biologics (Cayman)

HKG-2269
Healthcare Biotechnology
Rank #1563
Market Cap 12.23 B
Volume 21.78 M
Price 3.04
Change (%) 0.85%
Country or region Hong Kong Hong Kong

WuXi Biologics (Cayman)'s latest marketcap:

12.23 B

As of 05/19/2025, WuXi Biologics (Cayman)'s market capitalization has reached $12.23 B. According to our data, WuXi Biologics (Cayman) is the 1563th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 12.23 B
Revenue (ttm) 2.54 B
Net Income (ttm) 456.50 M
Shares Out 4.06 B
EPS (ttm) 0.11
Forward PE 20.00
Ex-Dividend Date n/a
Earnings Date 03/21/2025
Market Cap Chart
Data Updated: 05/19/2025

WuXi Biologics (Cayman)'s yearly market capitalization.

WuXi Biologics (Cayman) has seen its market value drop from HK$419.91 B to HK$95.65 B since 2020, representing a total decrease of 77.22% and an annual compound decline rate (CAGR) of 28.65%.
Date Market Cap Change (%)
05/19/2025 HK$95.65 B 32.67%
12/31/2024 HK$72.10 B -42.32%
12/29/2023 HK$124.99 B -50.53%
12/30/2022 HK$252.68 B -35.37%
12/31/2021 HK$390.94 B -6.9%
12/31/2020 HK$419.91 B

Company Profile

About WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc. is an investment holding company that delivers end-to-end solutions for biologics discovery, development, and manufacturing. Serving global markets, including China, North America, Europe, and Asia-Pacific, the company operates through two key segments: Biologics and XDC.

Core Services & Solutions

  • Comprehensive biologics discovery, from concept to IND (Investigational New Drug).
  • Contract research, development, and manufacturing (CRDMO) services.
  • Proprietary platforms including WuXiBody, SDArBodY, T cell engager, and Single B Cell Cloning Technology.
  • Process development, CMC (Chemistry, Manufacturing, and Controls), and downstream solutions.
  • Vaccine CDMO services and related business operations.

Additional Offerings

  • Biopharmaceutical technology consultation.
  • Testing and development of diagnostic technologies.
  • Sales, marketing, and clinical manufacturing services.
  • Production and distribution of medical products.
  • Investment and material supplier activities.

Strategic Partnerships

The company collaborates with leading biotech firms, including a research service agreement with BioNTech SE to develop next-generation monoclonal antibody therapeutics.

Company Background

Founded in 2014, WuXi Biologics is headquartered in Wuxi, China, and has established itself as a key player in the global biologics industry.

Frequently Asked Questions

As of 05/19/2025, WuXi Biologics (Cayman) (including the parent company, if applicable) has an estimated market capitalization of $12.23 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

WuXi Biologics (Cayman) global market capitalization ranking is approximately 1563 as of 05/19/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Hong Kong
Founded 2014
IPO Date n/a
Employees 12,575
CEO Zhisheng Chen
Sector Healthcare
Industry Biotechnology
Address No. 108, Meiliang Road
Wuxi, 214092
China
Website https://www.wuxibiologics.com
People Also Watch
VRTX
436.33 0.85%
CSL Limited
155.83 0.85%
REGN
587.55 0.85%
KRX-207940
733.99 0.85%